On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...
MASH is the new term for NASH. MASH stands for metabolic dysfunction–associated steatohepatitis, a type of liver disease. The liver disease used to be referred to as non-alcoholic steatohepatitis, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback